Stem Cell Clinic

Brooks Koepka had stem cell treatment on knee during offseason – ESPN

LAS VEGAS -- Brooks Koepka spent the majority of his short offseason recovering from stem cell treatment on his left knee, he said Wednesday.

Koepka, the No. 1 player in the world golf ranking, returns to competition this week in the Shriners Hospitals for Children Open in Las Vegas.

After his pro-am round Wednesday, Koepka said he had treatment on his patella on Aug. 25, the day after the PGA Tour season ended at the Tour Championship. He said he was limping for a few days because the treatment was painful, but he was excited about finally feeling whole.

"My knee was bugging me from about March on," Koepka said, adding that the final four months were a "struggle."

Koepka won three titles last season, including the PGA Championship -- his fourth major.

He is the third player from the top 10 in the world golf ranking to have work done on his knee during the offseason, joining Dustin Johnson and Tiger Woods. None was too serious, as Woods plans to return in three weeks at the new tournament in Japan. Johnson is likely to return at the Hero World Challenge in the Bahamas the first week of December, followed by the Presidents Cup in Australia.

Koepka never talked about injury during the season. He said his knee made it difficult to walk down hills and that it kept him from practicing. He returned to practice a little over a week ago and feels this is the most prepared he has felt going into a tournament in some time.

With all that, he still managed to have three wins, lead the PGA Tour money list and join Jack Nicklaus, Woods and Jordan Spieth as the only players to finish among the top four in every major. Koepka was runner-up at the Masters and U.S. Open.

It just wasn't good enough to be voted PGA Tour player of the year. That award, voted on by players, went to Rory McIlroy, whose three victories included The Players Championship and the Tour Championship, which gave him the FedEx Cup for the second time.

"I don't play for awards," Koepka said Wednesday. "I play to win tournaments."

He also used an NBA reference, suggesting everyone knows that LeBron James has been the best in basketball for the last decade or more.

"LeBron has won only four MVPs," Koepka said. "I'm pretty sure he's been the best player."

Read the rest here:
Brooks Koepka had stem cell treatment on knee during offseason - ESPN

Early clinical trial for ALS sufferers shows biotech firm ‘on the right track’ – The Times of Israel

Kadimastem Ltd., a biotechnology firm that develops cell therapies, said it has received promising interim results from a first group of patients treated with its new therapy for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease, a fatal neurodegenerative condition that causes the loss of muscle control.

Looks like we are on the right track, said Rami Epstein, the CEO of Kadimastem, in a phone interview. The interim results are important because they demonstrate that we have managed to inject the live cells into a human body without any treatment-related significant adverse effect, while also showing a measurable therapeutic effect. Our cell therapy managed to significantly slow down the disease progression and halt deterioration of the disease.

The cell therapy aims to slow or even halt the progression of the disease and improve patients quality of life and life expectancy, he said.

Get The Start-Up Israel's Daily Start-Up by email and never miss our top storiesFree Sign Up

ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is two to five years. According to the ALS Therapy Development Institute, there are approximately 450,000 ALS patients worldwide, 30,000 of them in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to $6 billion.

Reserachers at Kedimastems Good Manufacturing Practice (GMP)-compliant production facilities in Nes Ziona, Israel (Hagit Stavinsky)

In a filing to the Tel Aviv Stock Exchange last week, the firm said that the treatment administered to one group of patients in a Phase 1/2a clinical trial held in Israel apparently caused a significant slowdown in the progress of the disease and was found to be safe.

ALS is a devastating disease and there is a critical need for new treatments to more effectively slow down or halt its rapid progression, said Dr. Marc Gotkine of the Department of Neurology at Hadassah Medical Center, Jerusalem, and the principal investigator of the trial. These preliminary results on a small subset of patients are encouraging, as the treatment seems to be safe, at this lower dose.

The initial data analysis appears to demonstrate a slowing down of the reported deterioration rate over the three months following treatment, he said.

This is a positive, but preliminary results and the final results should be awaited, analysts Frost & Sullivan said in an investor note filed with the Tel Aviv Stock Exchange.

Should the final results expected at the end of 2019 for this phase 1/2a trial also prove positive, this will position Kadimastem as a potential major player in the ALS market and will have positive effect also on firms value, the analysts said. This will also serve as proof of the potential of the companys platform which can be used to treat additional indications in the future.

Prof. Michel Revel, the CSO and founder of Kadimastem (Courtesy)

The company, whose shares are traded on the Tel Aviv Stock Exchange, was founded by Prof. Michel Revel, who serves as the companys chief scientific officer. Revel is an emeritus faculty member of the Weizmann Institute of Science and a winner of the Israel Prize, the nations greatest accolade. He is also the creator of Rebif, a multiple sclerosis drug now marketed by Merckand selling for billions of euros globally.

Revel founded Kadimastem in 2009 with Yossi Ben-Yossef, based on cell therapy research Revel had conducted at the Weizmann Institute. Such research focuses on live cells transplanted into the body to replace malfunctioning, disease-causing cells.

In the cell therapy methodology developed and implemented by Kadimastem, we take embryonic stem cells, expand them into large quantities, and differentiate them into specializing cells, he said. Our cells are injected into the patient, replacing and compensating for the biological activity of the damaged cells.

A researcher working in the lab of Kadimastem, in Nes Ziona, Israel (Hagit Stavinsky)

The firm operates in two main spheres: neurological diseases, with the aim of replacing nervous system cells that have stopped functioning; and type 1 diabetes, in which cells that secrete the insulin needed to absorb sugar stop functioning. We develop cells that secrete insulin and regulate blood sugar levels, he said.

In the neurological sphere, the firm has started clinical trials, still at very early stages and on a small group of patients, to replace astrocyte cells,which are responsible for supporting neurons that enable muscle activity. In ALS patients, as a result of dysfunctional astrocytes, the neurons degenerate and muscle control deteriorates as the disease progresses.

All of the ALS patients die eventually, said Epstein, as there is no known cure for the disease. As the disease progresses, patients eventually lose control of their respiratory muscles, including the diaphragm, causing severe respiratory complications, the most common cause of death for ALS patients.

In their work at Kadimastem, the researchers differentiated embryonic stem cells into astrocytes. Scientific literature has indicated that astrocyte cells play a substantial role in supporting malfunctioning cells in ALS and other neurodegenerative diseases, said Revel in a statement issued by the firm.

Kadimastems lab in Nes Ziona, Israel (Hagit Stavinsky)

The patients had these cells injected into their spinal cord, where they secreted various factors that act as goodies, said Epstein. In animal trials, these cells created a protective layer around damaged neurons preventing further deterioration and maintaining and supporting the remaining neuron and muscle activity.

The cells were also able to secrete factors that remove toxic materials accumulated on the damaged neurons, thus acting as a garbage truck, taking toxic and damaging materials away from the neurons, Epstein said.

Now, the Phase 1/2a clinical trial conducted in humans is the first one ever, worldwide, in which live astrocyte cells, our own proprietary AstroRx cells, have been transplanted into humans, he said.

The trial, which started last year, is being conducted at the Hadassah Ein Kerem Medical Center in Jerusalem on 21 patients divided into four groups.

Each group receives our AstroRx cells, Epstein explained, saying the firm is very excited about the interim results of the first group, which got the lowest dose of the cells some 100 million cells injected into the spinal cord fluid of each patient.

The results are very significant for ALS patients and for us, he said. We hope that in the other groups we will see improved or prolonged efficacy and also safety. Kadimastem has advanced the quest to find a treatment for ALS but has also shown that the company has the ability to differentiate cells into clinical grade functional cells, fit for injection and also effective in humans.

A second cohort of patients, forming part of the same ongoing Phase 1/2a clinical trial, will be getting 250 million cells; group three will get two doses of 250 million cells each, to see if repeated treatments will yield enhanced results; and the fourth group is expected to receive a dose of 500 million AstroRx cells.

The journey ahead is still very long, Epstein emphasized, and it will be years before a drug will be made available to patients. The current Phase 1/2a trial is expected to conclude at the end of 2020, and then an additional trial will start, hopefully with a larger group of patients and in a number of medical centers.

Shares of the company have declined 2.1% in the past 12 months, bringing its market value to NIS 74 million ($21.2 million), as of end of day Wednesday.

Read more here:
Early clinical trial for ALS sufferers shows biotech firm 'on the right track' - The Times of Israel

"I have talked about this treatment for so long… I finally gave in and set up the GoFundMe page. It killed me to have to do it." – Echo…

AN ordinary man with ordinary interests, Patrick Keane loves life, even though it has become more of a challenge than ever before.

He cannot play a round of golf or go for a walk by the beach any more. But he doesnt want pity and exudes positivity. So he enjoys soaking in the sea air around Clonea or Garryvoe without stretching his legs.

But reality has a way of crashing through the faade at times, no matter how strong you are.

For Patrick, it can be when he wakes up and cannot feel his legs, or loses his train of thought, or misses his mouth when trying to eat because he cannot feel the spoon in his hand. Or if he gets out of bed and falls and screams at himself, Just get up will ya, ya fool!

But the man known as Pa to his friends, or Patch to his mother Margaret, brother Paul and sisters Yvonne and Elaine, dusts himself down, drags himself back to an upright position and goes about taking on the day in as fearless a fashion as possible, given what he must encounter now and the knowledge of what lies ahead.

Multiple sclerosis affects the central nervous system, the brain and the spine, and while the rate of degeneration differs for all, there is no escaping the degeneration. Ireland has 8,000 sufferers with apparently no cure.

Patrick, who was diagnosed in January, 2009, is not without hope however. A doctor, Denis Federenko, has been providing stem cell transplants to people from all over the world at the AA Maximov Hospital in Moscow, with some success, by wiping out the faulty immune system with drugs used to treat cancer and replacing it with stem cells taken from the patient.

Irish comedian, Stephen Garland is one who underwent treatment in November, 2016, having been told he was around six months away from being confined to a wheelchair.

He returned home just before Christmas that year and has thrived since, even writing a show about his journey to Russia and back.

Garland brought his creation, Post-Disposed, back to the world-renowned Edinburgh Fringe Festival in August, confirming his continuing improved health.

The treatment costs between 50,000 and 60,000 including aftercare and other expenses. It can be hard to ask for help but so many people have extended a hand to Patrick, without ever being asked. People Patrick doesnt know from Adam or Eve have even contributed to his cause and it moves him to tears.

Time is against the Corkman however, because if his condition exceeds 6.5 on a scale of 0-8, he will not be taken on. At present, he is between 5.5 and 6, and has been accepted, but clearly the treatment must take place sooner rather than later.

To that end, a Breakfast With The Stars event is taking place at The Park Hotel, Dungarvan on Thursday, October 10. Tipperarys All-Ireland-winning manager, Liam Sheedy and multiple champion jockey Davy Russell will regale patrons with stories from their careers, prompted by MC Marty Morrissey.

All proceeds will go towards funding Patricks treatment and ancillary expenses. Ticket purchasing details are below.

Here is more about Patricks story...

************

LAYLA walks into the family home in Ballinroad, just outside Dungarvan. It was Patrick who named her, after the Eric Clapton song that he happened to be listening to when the family were discussing what to call the now 12-year-old dog.

Music is a boon, a real infusion of energy, pumping the blood, making him feel like he could jump out of his skin and dance like the old days. He cant but that burst of adrenaline is a godsend.

I have the car adapted with hand controls, Patrick explains. I dont use my feet for driving. Push and pull the lever in the car.

On a Sunday morning I love nothing better, especially when I am down at home. Head down the coast road to Tramore, listen to a bit of music.

I would listen to absolutely anything. I am influenced by dads taste in music. All the older stuff, 70s, 80s rock music kind of stuff. You could find me listening to dance music two minutes later. Once it has a beat I couldnt care less.

Patricks dad, Richie Keane, was a hard worker, who was brilliant with his hands and especially with cars. And all his life he had a smaller shadow. The son looked up to the father like he was Superman.

When he was sick and on his last legs, talking through the window from the house he taught me how to take the sump off my car because it was cracked and leaking oil. He was able to guide me through it without looking at it, word for word.

I restored a Jeep that he left when he passed away. It was a 1983, same age as myself, Mercedes jeep. Very rare, like hens teeth. Restored it to about 25,000 to 30,000 worth.

I had to sell it. I couldnt drive it anymore because the leg was so bad. That was hard. That was the last connection. It was something I had to remember him by. The day I saw that go out the drive was tough.

Richie died in November, 2008, around the time of Patricks 25th birthday. Richies mother passed away two weeks later. Patrick was diagnosed with MS in January, 2009. Already a celiac and diabetic, he was accustomed to restrictions and putting up with things. This was a different stratosphere though.

It began with losing his balance and the development of numbness down his right side.

I went to the doctor, and I think, by the look on his face, he knew there was something not right. He sent me to Ardkeen (Hospital) and I got checked out. They had me in isolation for about a week. Then I was told it was MS.

I didnt know what it was but it was something I heard from a conversation when I was younger, That poor fella has MS. I didnt know I would end up the way I am now.

I have friends since that have been diagnosed after me that I have gotten to know from reaching out. There are a couple of them in a wheelchair. As it progresses, that is where you are heading. But there is a gentleman up the road and he must have it for 20-something years. Unless someone told you, you wouldnt know he has MS.

Part of the difficulty of dealing with MS is that no two cases are alike. Keeping active, having physiotherapy regularly and working are advantages and Patrick has not declined as quickly as others because of that.

But he has hit the secondary stage, where there are cognitive problems and, in particular, his short-term memory is affected.

People say to me, do you get pain with it? I dont know what new pain or old pain is. I just get on with. I have my days where I whinge and moan and cry. God knows I have them. But there is people out there worse off. I have what I have.

It could get worse. Now that it is gone to progressive MS, it probably will. When or how long? Who knows?

It is a horrible disease, there is no two ways. But you get up, get on with it, and do what you can.

He went to Australia not long after the diagnosis. It was a real gesture of defiance, one that probably scared his mother but he knew too that it might well be a case of now or never.

A blocklayer by trade, Patrick eventually had to give that up as his coordination worsened and he nearly fell off a roof. He is on crutches now for three years and would not be able to catch a football if you threw it at him. He wears a leg cast too, to reduce the instances of tripping himself up, without eradicating them totally. He has a mobility scooter.

A 35-year-old man doesnt dream about a mobility scooter, he wants a flash sports car. But it allowed me to go down to the Greenway for the first time. That was nice, to be on the Greenway, to be out, and see the whole lot of it, it was lovely. But watching other people cycle off down killed me.

My two nephews were out the front playing soccer. I used to do the exact same thing. They were saying Patrick, are you coming out to play? I said I would love to but that gets you. Its the simple little things.

Katie, my partner, I dont know where I would be without her. My mam, the girls and my brother, they are fantastic. They have been with me since the start of it.

I decided I want to be independent. If I didnt have the car I dont know what I would be doing. That is my freedom. I can get into the car, go to the shop for coffee. I will get there. I will get the same place as anyone else will, but it will take me longer.

He lives in Cork with Katie and her son Aaron, and works for Voxpro, who have been tremendously supportive. If he were housebound, he would wither.

I am an outgoing guy. I would chat away, waffle on about anything for hours on end. But you take that away I dont know have I changed since the diagnosis.

I have tried to remain as positive as possible but sometimes its hard. Simple little things you take for granted. Just run out there to get the clothes off the line. Now I have had to get handrails put into the house so that I can get up when I trip and fall.

I would wake in the mornings and the legs are like jelly. They shake, you cant control it, you let them shake out and that could be for 20 or 30 seconds. Real spasticity and stiffness in the legs. With the heat during the summer, I sat in the car with the air con on. I would be good for doing weather forecasta. I know what its like when I wake up in the morning, ever before the curtains are pulled. I feel it in my body.

He has been trawling for potential treatments, along with his medical team. Dr Federenkos work stands up to inspection. Stopping the MS in its tracks without the need for further medication would be a tantalising prospect.

Reversing the effects is something he dare not even contemplate, though the treatment has had that effect in Garland and many others.

Being given the green light, after Dr Federenko reviewed his case and medical records, was like an infusion in itself. Patrick details every step of the treatment and though it sounds daunting, it isnt compared to the alternative.

He set up the GoFundMe page (https://www.gofundme.com/f/stop-ms-progression-with-stem-cells-transplant) and was staggered by the reaction. Meanwhile, the local community has rallied, as have his work colleagues and friends, organising fund-raiser after fund-raiser. People he didnt know had events. He finds it hard to process.

To ask for someones help, it is a sign that you are not able. I have talked about this treatment for so long and I got so bad in my legs and balance and everything, I finally gave in and set up the GoFundMe page. It killed me to have to do it.

There was a donation yesterday on GoFundMe from Jamaica. I dont know the person but they found it in their heart to say, There you go. People said to me, Sorry I cant give you too much, I want to give you more. If it is a euro or 20 cent, it could be that 20 cent or euro that gets me over the line.

Whatever happens, he will not give up because it is what he learned when he was Richies shadow: It is instilled in me from dad, I would always have looked up to him. Even now, since he has passed away, I would always say to myself, What would he do? Would he have approved of that? He would always say to stick at something until you get it. If you are going to start something, do it. Just dont walk away from it.

Breakfast With The Stars, featuring Tipperary manager Liam Sheedy, one of the all-time greats of National Hunt racing Davy Russell and RTs Marty Morrissey, takes place at The Park Hotel on Thursday, October 10. To book a table of 10 for 1000 contact Michael Ryan (087 2585299) or The Local Bar (058 41854).

Donations can also be made to Patrick Keanes GoFundMe pagehttps://www.gofundme.com/f/stop-ms-progression-with-stem-cells-transplant

Continued here:
"I have talked about this treatment for so long... I finally gave in and set up the GoFundMe page. It killed me to have to do it." - Echo...

Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) – Markets Gazette

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

Request For Free Sample Report : https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#requestforsample

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#inquiry

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact:+ 919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Here is the original post:
Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) - Markets Gazette